Litcius/Paper detail

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies

George Sakoulas, Paul B. Eckburg, Maria Amodio-Groton, Amy Manley, Evan Tzanis, Anita Das, Robert Noble, Paul C. McGovern

2021Open Forum Infectious Diseases13 citationsDOIOpen Access PDF

Abstract

In this post hoc analysis of the 63 patients with secondary bacteremia enrolled in the 3 omadacycline phase 3 studies of acute bacterial skin/skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), we determined that omadacycline is a viable therapeutic option for appropriate patients with secondary bacteremia.

Topics & Concepts

MedicineBacteremiaBacterial pneumoniaPneumoniaInternal medicineIntensive care medicineMicrobiologyAntibioticsBiologyAntimicrobial Resistance in StaphylococcusAntibiotic Use and ResistanceAntibiotic Resistance in Bacteria
Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies | Litcius